Frontiers in Immunology
Cure8 research brief
Why This Matters
Spatial mapping of immune niches in refractory UC identified tissue signatures (neutrophil-rich ulcer-bed niches and TLS/plasma-cell programmes) that were associated with failure to respond to biologic drugs across adult datasets, which could help explain and eventually predict who will not benefit from certain biologics.
Who Should Pay Attention
Clinicians and researchers studying UC treatment response and biomarker development; adult patients with medically refractory UC and their caregivers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study used high-resolution spatial transcriptomics (10x Visium HD) on full-thickness, surgically resected colon samples from a small set of adults with medically refractory ulcerative colitis and controls to map immune–stromal niches across the tissue.
The authors identified an “Acute Neutrophil Niche” at ulcer beds, tertiary lymphoid structure (TLS)–associated humoral programmes in submucosa, and plasma-cell survival signalling; they derived niche-based signatures that were associated with biologic non-response across several adult cohorts and validated some cellular findings in a mouse colitis model.
The paper suggests these spatial niche signatures could help explain why some patients do not respond to anti-TNF or anti-integrin biologics and might inform future biomarker-driven treatment selection, but prospective clinical validation is still needed.
Keep In Mind
Results are based on high-resolution spatial transcriptomics of a small set of resected samples and cross-cohort analyses; prospective validation is required before these signatures can guide treatment decisions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Immunology
PublisherFrontiers Media SA
AuthorsQingquan Bai, Runyang Li, Zhengjin Liu +17 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 25, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Response-aware molecular subtyping of ulcerative colitis for patient stratification via interpretable machine learning.
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
The Association of microRNA-145 and microRNA-191 with Therapeutic Response in Patients with Inflammatory Bowel Disease
Non-invasive blood biomarkers that predict who will respond to therapy could help personalize treatment and avoid ineffective medications. This study identifies plasma miR-145 and miR-191 as potential predictors of...
Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study.
If validated, metabolite patterns could help predict which children will reach remission on vedolizumab, potentially guiding treatment choices and avoiding ineffective therapy.